Abivax stock crashes as safety fears overshadow bowel disease drug trial win

Abivax shares fell 31% even after the French biotech reported strong late-stage data for obefazimod, its experimental treatment for ulcerative colitis. The once-daily oral therapy met the main goal and all key secondary endpoints in a Phase 3 maintenance study, strengthening the case for a potential new option in a market still led by injectable biologics and other advanced treatments.